Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin Pediatric Study in Type 2 Diabetes Mellitus
2022-501085-21-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Ertugliflozin arm with Placebo arm (2 arms). Primary endpoints: Change from Baseline in Hemoglobin A1C (HbA1C) at 24 weeks (pooled ertugliflozin 5 mg and 15 mg versus placebo), Number of Participants Who Experience an Adverse Event (AE) over 24 weeks and 3 more. Started Nov 2019; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-501085-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501085-21-00.